Company Management
Alton L. Boynton, Ph.D.(aged 63) President; Chief Executive Officer
Dr. Boynton co-founded the Company and has served as its Chief Scientific Officer and as a director since 1998. Dr. Boynton was appointed as Chief Operating Officer in August 2001, and President in May 2003. Dr. Boynton has also served as director of the Department of Molecular Medicine of Northwest Hospital from 1995 to 2003 where he coordinated the establishment of a program centered on carcinogenesis. Prior to moving to Seattle, Dr. Boynton was associate director of the Cancer Research Center of Hawaii at The University of Hawaii, where he also held the positions of director of Molecular Oncology of the Cancer Research Center and professor of Genetics and Molecular Biology.
Marnix L. Bosch, Ph.D.(aged 48) Chief Technical Officer
Dr. Bosch joined the Company in 2000 and served as Vice President for Vaccine R&D from July 2001 to December 2006. Dr. Bosch currently serves as the Company's Chief Technical Officer. Prior to joining the Company, Dr. Bosch was a member of the faculty of the Department of Pathobiology at the University of Washington and he continues to serve that Department as an Affiliate Associate Professor. He worked at the National Institutes of Health (Bethesda, MD) and the National Institutes of Health and Environmental Protection (Bilthoven, the Netherlands) prior to joining the University of Washington. He has authored more than 40 research publications in virology and immunology, and is an inventor on several patent applications on dendritic cell product manufacturing. Dr. Bosch obtained his Ph.D. in Medicine at the University of Leiden, the Netherlands, in 1987 and earned an MBA from the University of Washington in 2003.
 Anthony P. Deasey, F.C.A.(aged 58) Senior Vice President of Finance and Chief Financial Officer
Mr. Deasey joined the Board in September 2007. Mr. Deasey has extensive experience in the financial arena with both publically and privately held companies. He most recently served for seven years as Executive Vice President and Chief Financial Officer of Celsion Corporation (AMEX:CLN), a development stage company developing heat activated liposomal drug delivery systems. Prior to Celsion Mr. Deasey was Chief Financial Officer of Church & Dwight Co. Inc. (NYSE:CHD), Rollerblade and World Kitchen Inc. and held increasingly senior positions in the international operations of Chesebrough Ponds Inc. and Price Waterhouse. Mr. Deasey is a fellow of the Institute of Chartered Accountants in England and Wales.
|
